Medizinprofessor fordert Professoren auf, ihre Nebeneinkünfte zu offenbaren
Deutschlandfunk 13.1.2011
Website
Audio on demand
14. Januar 2011
3. Dezember 2010
Government oversight agency calls on NIH to ban ghost-writing
Der einfachste Zugang und eine Reihe von interessanten Links in dem Blog von Alison Bass:
"Much has been written about the insidious practice of ghost-writing in medical research in this and other blogs and news articles. Even Dr. Francis Collins, the director of the National Institutes of Health (NIH), expressed dismay over the problem in a C-SPAN interview last year, calling it a threat to the "integrity of science." So far, however, not much has been done to curb such abuses"
9. November 2010
Die öffentliche Reputation der Pharmaindustrie in den USA im Jahr 2009
Physician Professionalism
and Changes in Physician-Industry Relationships From 2004 to 2009. Arch Intern Med 2010;170(20):1820-26.
Campbell EG, Rao SR, DesRoches CM, Iezzoni LI, Vogeli C, Bolcic-Jankovic D, et al.
Abstract
Campbell EG, Rao SR, DesRoches CM, Iezzoni LI, Vogeli C, Bolcic-Jankovic D, et al.
Abstract
7. November 2010
Information from Pharmaceutical Companies
and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review.
PLoS Medicine 19.10.2010 Link
PLoS Medicine 19.10.2010 Link
2. November 2010
Richard Smith on editors’ conflicts of interest
27. Oktober 2010
Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study
Conclusions
Publication of industry-supported trials was associated with an increase in journal impact factors. Sales of reprints may provide a substantial income. We suggest that journals disclose financial information in the same way that they require them from their authors, so that readers can assess the potential effect of different types of papers on journals' revenue and impact.
Link
Meldung in aerzteblatt online 27.10.2010
Beitrag im Forum Gesundheitspolitik
Publication of industry-supported trials was associated with an increase in journal impact factors. Sales of reprints may provide a substantial income. We suggest that journals disclose financial information in the same way that they require them from their authors, so that readers can assess the potential effect of different types of papers on journals' revenue and impact.
Link
Meldung in aerzteblatt online 27.10.2010
Beitrag im Forum Gesundheitspolitik
20. Oktober 2010
Modeling in pharmacoeconomic studies: Funding sources and outcomes
International Journal of Technology Assessment in Health Care 2010), 26: 330-333
Abstract
Conclusions:
The review found a substantial share of studies supported by the pharmaceutical industry, almost all concluding in favor of the drug studied, without any unfavorable conclusions at all. These results confirm also in the field of pharmacoeconomic studies that the best way of limiting confounding factors is by clearly distinguishing assessors from manufacturers and marketers of any new technology.
Abstract
Conclusions:
The review found a substantial share of studies supported by the pharmaceutical industry, almost all concluding in favor of the drug studied, without any unfavorable conclusions at all. These results confirm also in the field of pharmacoeconomic studies that the best way of limiting confounding factors is by clearly distinguishing assessors from manufacturers and marketers of any new technology.
Abonnieren
Posts (Atom)
Posts
